SweetValueLab
Write for us

Novo Nordisk A/S — Financial Statements & Ratios

NVO
NYSEHealthcareDrug Manufacturers - GeneralCIK 0000353278novonordisk.comAbout NVO
Last close · Oct 30, 202640.00+0.86 (+2.20%)

Key indicators

Revenue329.4BTTM+5.6% on a year earlier+15.6% a year, FY2018–FY2025
Fiscal yearFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTMFY2026EFY2027EFY2028E
Growth
111.8B 122.0B+9.1%126.9B+4.0%140.8B+10.9%177.0B+25.7%232.3B+31.3%290.4B+25.0%309.1B+6.4%329.4B+5.6%304.4B 309.6B 328.7B
— 9.1% 4.0% 10.9% 25.7% 31.3% 25.0% 6.4% 5.6% -1.5% 1.7% 6.2%
$7.97 $8.19+2.8%$9.01+10.0%$10.37+15.1%$12.22+17.8%$18.62+52.4%$22.63+21.5%$23.03+1.8%$26.19+5.0%$22.25 $22.10 $23.88
Profitability
84.2% 83.5%−0.7 pt83.5%−0.0 pt83.2%−0.3 pt83.9%+0.7 pt84.6%+0.7 pt84.7%+0.1 pt81.0%−3.7 pt80.6%−3.3 pt· · ·
42.2% 43.0%+0.8 pt42.6%−0.4 pt41.7%−1.0 pt42.3%+0.6 pt44.2%+1.9 pt44.2%+0.0 pt41.3%−2.9 pt43.1%−2.6 pt· · ·
34.5% 31.9%−2.6 pt33.2%+1.3 pt33.9%+0.7 pt31.4%−2.5 pt36.0%+4.7 pt34.8%−1.3 pt33.1%−1.6 pt35.3%−0.3 pt· · ·
74.5% 67.6%−6.9 pt66.5%−1.1 pt67.5%+1.0 pt66.5%−1.0 pt78.5%+12.0 pt70.4%−8.1 pt52.8%−17.6 pt— · · ·
Cash
32.2B 35.6B+10.4%29.9B−16.0%47.6B+59.4%64.1B+34.7%70.0B+9.2%69.7B−0.5%29.0B−58.4%48.9B−20.6%· · ·
28.8% 29.1%+0.3 pt23.5%−5.6 pt33.8%+10.3 pt36.2%+2.4 pt30.1%−6.1 pt24.0%−6.2 pt9.4%−14.6 pt14.8%−4.9 pt· · ·
34.6B 34.7B+0.4%37.0B+6.4%41.0B+10.8%49.4B+20.6%61.7B+24.9%64.3B+4.3%53.2B−17.4%— · · ·
Balance sheet
0.01x 0.08x+0.07x0.16x+0.09x0.38x+0.21x0.31x−0.07x0.25x−0.06x0.72x+0.46x0.67x−0.04x0.63x+0.04x· · ·
4.85B 4.76B−1.9%4.68B−1.6%4.61B−1.6%4.54B−1.3%4.49B−1.1%4.46B−0.7%4.45B−0.3%4.44B−0.2%· · ·

E = analyst consensus (revenue and EPS only). TTM = the twelve months to Jun 30, 2026: the last fiscal year, plus the quarters since, less the same quarters a year earlier. From the 10-K and the 10-Qs since; the shaded column is the latest period.